Rimantadine hydrochloride (ox-methyl-1-adamantanemethylamine hydrochloride) is an amantadine analog that has shown greater activity than amantadine against some influenza A viruses in vitro, and in experimental influenza A virus infection in mice (2, 5, 6) . Previous studies have found similar therapeutic activity, reflected by faster defervescence and resolution of symptoms as compared with placebo treatment, when the drugs have been given to patients with uncomplicated influenza (4, 8, 9) . However, patients tolerate rimantadine significantly better than amantadine when these drugs are administered in equivalent doses (200 or 300 mg/day) to healthy (1, 3) or influenza virus-infected (8) adults. The differences in toxicity relate to differences in plasma concentrations and pharmacokinetics between the drugs (3, 3a, 7 The clinical effects of rimantadine treatment were asover 1 year, after which she was lost to follow-up. sessed by measuring oral temperatures four times per day Earlier placebo-controlled studies documented that (Table 2) and by the subjective scoring of systemic and rimantadine (150 mg twice daily for 10 days) was associated respiratory symptoms by the infected students (Table 3) .
with a reduction in the duration of fever and symptoms in The two treatment groups had similar maximum oral tem-H3N2 subtype influenza A virus-infected prisoners (4, 9). At peratures (Table 2 ) and symptom scores (Table 3) on enrollequivalent doses (100 mg twice daily for 5 days), rimantadine ment in the study. Placebo recipients experienced a gradual was associated with a somewhat slower defervescence and reduction in mean temperature, whereas rimantadine-treated resolution of symptoms compared with amantadine, alpatients defervesced rapidly and had significantly lower though both drugs were significantly more effective than mean maximum temperatures on treatment days 2 and 3 placebo (8) . Since rimantadine is associated with signifi- (Table 2 ). On treatment day 3, all seven rimantadine recipicantly lower plasma concentrations than amantadine, and ents were afebrile (with a maximum oral temperature of has an approximately twofold longer plasma elimination -<990F), compared with none of the seven placebo recipients half-life (3a), the current study used a single daily dosage (P < 0.01). The mean ± standard deviation duration of the regimen with a modified loading scheme, in which the fever (temperature, >99°F) from the onset of therapy was 31 majority of rimantadine recipients received 300 mg on day 1 + 22 h in the rimantadine group, compared with 68 ± 8 h in and 200 mg/day thereafter. The results indicated a prompt the placebo group (P < 0.01, Mann-Whitney U test). Simiimprovement in the rimantadine group with significant de- creases in fever by treatment day 2. The average decrease in the duration of fever (37 h) compared with the deviation in the placebo group was similar to observations reported previously (28 h) for oral rimantadine (150 mg twice daily for 10 days) in treating adults with uncomplicated H3N2 subtype influenza A virus infection (9) . In summary, oral rimantadine given once daily was generally well tolerated and associated with significant clinical benefits in uncomplicated H3N2 subtype influenza A virus infection. Because of its therapeutic efficacy and lower potential for side effects (1, 3, 8) , rimantadine may be preferable to amantadine for treating influenza A virus infections.
